MUSK and myasthenia gravis: While these agents effectively inhibit acetylcholinesterase activity at the neuromuscular junction, they demonstrate significantly reduced clinical benefit in MuSK-positive MG, as the primary pathophysiology involves antibody-mediated disruption of MuSK-dependent postsynaptic signaling rather than solely acetylcholine deficiency.